[Ratio of neuromediator amino acids in a comparative analysis of the stress protective effects of delta-sleep inducing peptide and piracetam].
Mendzheritskiĭ AM, Uskova NI, Lysenko AV, Matsionis AE, Sametskiĭ EA · 1995 · Voprosy meditsinskoi khimii 41(5):16-19
What does this source report?
Combined DSIP and piracetam administration was associated with stronger stress-related effects on the balance of inhibitory and excitatory amino acids than individual compounds.
- Population and setting
- Rats exposed to one-hour restricted movement
- Evidence type
- Animal / experimental
- Preparation
- DSIP + piracetam
- Source language
- rus
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Biochemical animal endpoints; no evidence of human cognitive or occupational benefit. Full data are needed to assess additivity versus synergy.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Source access and review scope
Indexed metadata and abstract checked via PubMed / Europe PMC; full methods and risk-of-bias assessment pending.
Recorded source-check date: 2026-10-01. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Mendzheritskiĭ AM, Uskova NI, Lysenko AV, Matsionis AE, Sametskiĭ EA. [Ratio of neuromediator amino acids in a comparative analysis of the stress protective effects of delta-sleep inducing peptide and piracetam]. Voprosy meditsinskoi khimii 41(5):16-19 1995.
Molekul research summary: https://molekul.io/research/dsip-8553617. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
DSIP
A peptide first characterized in Swiss sleep research and later studied in Soviet/Russian analogue and stress-adaptation programmes. Ordinary DSIP, modified analogues and piracetam combinations have distinct evidence.
Piracetam
Piracetam, marketed as Nootropil, connects the original nootropic concept with Soviet clinical adoption and later operator, hypoxia and maritime research. Healthy-volunteer experiments, clinical reviews and combination proposals answer different questions.